自主的地域型臨床試験グループOGSGの実績と将来展望
2015
FU, IRI, OX不応KRAS野生型mCRCに対するIRI+Panitumumab 療法の日本人データ (OGSG1001)
IRI+Tmab併用療法の進行・再発HER2陽性胃癌既治療例に対する多施設第II相試験：OGSG1203 (HERBIS-5)
切除可能進行食道癌にたいする術前ACF vs DCF併用化学療法のランダム化比較試験：（OGSG1003）
A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)
A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)
Multicenter phase II trial of adjuvant S-1 plus Docetaxel for 6 months in patients with pathological stage III gastric cancer (OGSG1002)